Egypt spares no effort to boost cooperation with Sudan: Egyptian ambassador to Khartoum    EU foreign ministers condemn Turkish invasion of Syria    In a major shift, Syrian Kurds ally with Damascus to work side by side along the northern Syrian border    Egypt raises concerns about Ethiopia's GERD with German, Italian and Chinese envoys    Egypt's foreign minister begins tour of Central, Eastern Europe    US, European visa holders can now avail tourist visas to Saudi Arabia    Ambassadors, senior state officials, public figures at Korean National Day celebration    Egypt's Sisi, Ethiopian PM to meet in Moscow to discuss GERD issue    Delta Life Assurance's assets rise to 1.23bn Egyptian pounds June-end    IMF positive about Egypt's economic trajectory    Vitamins, omega-3 supplements improve autism symptoms    'Alarming upsurge' in measles has devastating impact, WHO warns    We achieved our objective in second half: Italy coach after Greece win    Formula One: Mercedes driver Bottas wins Japanese Grand Prix    We were not patient: Spain boss Moreno after Norway draw    Saudi Arabia to launch new logistics zone in Jeddah, open to private investors: Statement    Seven people killed, 15 missing after Japan typhoon    UK Labour's Corbyn unlikely to support deal between PM Johnson, EU    Tunisians select new president in final round of voting    KaramSolar in talks with 5 banks to secure billion-pound solar plants    10K fans to attend Egypt's friendly against Botswana in Alexandria: EFA    Egypt to increase daily oil output to70K in FY2020 – minister    Sisi, Ethiopia's PM agree to overcome obstacles in Nile dam talks    Why vacations are important for health    A brief history of the Cairo Opera House    Austrian Handke and Pole Tokarczuk win Nobel prizes for literature    Egypt's Zamalek president hopes 80,000 supporters attend Generation Foot match    Egypt's PM accuses Ethiopia of backtracking Nile water deals    In Photos: Alexandria Film Festival kicks off 35th edition    Farwell to Egyptian comic actor Talaat Zakaria    Egypt's PM, ministers to address parliament in Ethiopia    Barcelona paid €92 million to players in bonuses last season    Eating fish is linked to better sleep, higher IQ    Sisi stresses importance of technological universities, technical education    Egypt's Rowad Modern Engineering renovates 40% of Manial Palace    Grand Egyptian Museum's construction works 93% complete    Court sentences six to death, 41 to lifetime imprisonment violence related case    Trump says he would release Mideast peace plan after Israeli elections    ACWA Power compares 3 bids to supply production units for Luxor power station    What do you know about gold alloying?    NBE announces EGP 2.5m prizes for handball youth teams for their world achievements    Jennifer Lopez evokes Egyptian outrage post her North Coast performance    Al-Sisi honours Egypt's scholars on Science Day    IS claims responsibility for suicide bombing killing 63 in Afghan wedding    Political parties gear up for parliamentary, senate, local elections    Unprecedented Glory: Egypt win Men's U-19 World Handball Championship    12th National Egyptian Theatre Festival fuel up public theatre art scene    Ministry of Environment has a plan for "black clouds season"    







Thank you for reporting!
This image will be automatically disabled when it gets reported by several people.





Amid controversy: nasal spray for depression wins FDA panel backing
Published in Ahram Online on 17 - 02 - 2019

An advisory panel to the U.S. Food and Drug Administration on Tuesday voted in favor of Johnson & Johnson's experimental nasal spray, which has a compound similar to often-abused ketamine, bringing the drug closer to approval.
The panel voted 14-2 in favor of the drug esketamine, developed to treat major depression in patients who have not benefited from at least two different therapies, saying its benefits outweighed the risks. One panel member abstained from voting.
Esketamine is a chemical mirror image of anesthetic ketamine, which is also abused as a recreational party drug and goes by the street nickname “Special K”.
“I think esketamine has the potential to be a game-changer in the treatment of depression ... I use the term potential because the issues of cost and patient accessibility need to be addressed,” said Walter Dunn, who voted in favor of approval.
However, the panel members echoed concerns raised by FDA staffers on Friday regarding the increased risk of sedation, dissociation and higher blood pressure observed in the study.
Advertisement


The FDA recommended implementing a risk evaluation and mitigation strategy (REMS) program which included ensuring esketamine is only dispensed and administered under supervision.
“Ketamine is a nasty drug ... should (J&J's) drug get approved, I think a strong effort has to be given as part of REMS ... so that patients really know what they are getting themselves into,” said Steven Meisel, another member who voted ‘yes'.
Major depressive disorder affects over 300 million people globally. About 30 percent to 40 percent of these patients fail to respond to first-line treatments such as antidepressants, most of which take at least four weeks to show effect.
However, depression is a tricky area of development. Patients in clinical trials often show a big placebo response, masking the efficacy of the drug being tested.
Currently, Eli Lilly and Co's Symbyax is the only FDA-approved drug for treatment-resistant depression.
“There is a lot of potential for people that just want that quick fix. I really would be cautious,” said Kim Witczak, a panel member who voted ‘no'.
J&J's esketamine, used in combination with a newly prescribed antidepressant, works by restoring the nerve cell connections in the brain, leading to an improvement in depression symptoms.
The FDA, although not mandated to follow the panel's recommendation, is expected to announce its decision on esketamine by March 4.


Clic here to read the story from its source.